Corpus ID: 41240022

Pharmacogenomics of cystic fibrosis.

@article{Pollard2001PharmacogenomicsOC,
  title={Pharmacogenomics of cystic fibrosis.},
  author={H. Pollard and O. Eidelman and K. Jacobson and M. Srivastava},
  journal={Molecular interventions},
  year={2001},
  volume={1 1},
  pages={
          54-63
        }
}
  • H. Pollard, O. Eidelman, +1 author M. Srivastava
  • Published 2001
  • Medicine
  • Molecular interventions
  • Pharmacogenomics is becoming a frontline instrument of drug discovery, where the drug-dependent patterns of global gene expression are employed as biologically relevant end points. In the case of cystic fibrosis (CF), cells and tissues from CF patients provide the starting points of genomic analysis. The end points for drug discovery are proposed to reside in gene expression patterns of CF cells that have been corrected by gene therapy. A case is made here that successful drug therapy and gene… CONTINUE READING
    5 Citations

    Topics from this paper

    Cystic Fibrosis and the Use of Pharmacogenomics to Determine Surrogate Endpoints for Drug Discovery
    • 9
    CFTR activity and mitochondrial function☆
    • 53
    • Highly Influenced
    • PDF
    Arrays and Proteomics
    cDNA microarrays for pharmacogenomic analysis of cystic fibrosis.
    • 6